AVNT Stock Analysis: Avient | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 4.060m USD | 12M Return: 30.4% | US05368V1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.6M
EPS Trend: 94.4%
Qual. Beats: 1
Rev. Trend: 85.2%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Avient Corporation (NYSE: AVNT) is a specialty formulator of material solutions headquartered in Avon Lake, Ohio, operating across the United States, Canada, Mexico, Europe, South America, and Asia. Founded in 1885 and formerly known as PolyOne Corporation until its June 2020 rebranding, the company runs through two reporting segments: Color, Additives and Inks, which supplies custom color and additive concentrates, dispersions, and specialty ink systems, and Specialty Engineered Materials, which provides tailored polymer formulations and solutions for thermoplastic processors.
The company serves a broad range of end markets, including medical and pharmaceutical devices, food packaging, personal care, transportation, building products, wire and cable, textiles, appliances, and industrial applications. As a B2B specialty chemicals producer, Avient sells primarily through direct sales personnel, distributors, and commissioned sales agents, focusing on customized, value-added formulations rather than commodity chemical output.
- Specialty Engineered Materials revenue grows on healthcare and aerospace demand
- Europe industrial slowdown pressures Color Additives and Inks volumes
- Raw material cost volatility squeezes specialty chemicals profit margins
| Net Income: 171.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.53 > 1.0 |
| NWC/Revenue: 21.81% < 20% (prev 23.26%; Δ -1.45% < -1%) |
| CFO/TA 0.03 > 3% & CFO 162.9m > Net Income 171.8m |
| Net Debt (1.53b) to EBITDA (454.3m): 3.36 < 3 |
| Current Ratio: 1.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.2m) vs 12m ago 0.44% < -2% |
| Gross Margin: 32.15% > 18% (prev 32.63%; Δ -0.48% > 0.5%) |
| Asset Turnover: 54.89% > 50% (prev 53.07%; Δ 1.83% > 0%) |
| Interest Coverage Ratio: 3.10 > 6 (EBIT TTM 310.8m / Interest Expense TTM 100.3m) |
| A: 0.12 (Total Current Assets 1.53b - Total Current Liabilities 806.9m) / Total Assets 6.00b |
| B: 0.32 (Retained Earnings 1.94b / Total Assets 6.00b) |
| C: 0.05 (EBIT TTM 310.8m / Avg Total Assets 6.07b) |
| D: 0.69 (Book Value of Equity 2.44b / Total Liabilities 3.55b) |
| Altman-Z'' = 2.91 = A |
| DSRI: 1.03 (Receivables 553.5m/523.4m, Revenue 3.33b/3.25b) |
| GMI: 1.01 (GM 32.63% / 32.15%) |
| AQI: 0.98 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.02 (Revenue 3.33b / 3.25b) |
| TATA: 0.00 (NI 171.8m - CFO 162.9m) / TA 6.00b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of August 23, 2026, the stock is trading at USD 44.66 with a total of 637,084 shares traded. Over the past week, the price has changed by -3.63%, over one month by +21.03%, over three months by +31.88% and over the past year by +30.38%.
Current recommended Stop Loss: 42.70 (which is 4.4% or 1.3 ATR below the current price).
Avient has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AVNT.
- StrongBuy: 4
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.9 | 13.9% |
P/E Trailing = 23.418
P/E Forward = 13.4953
P/S = 1.2185
P/B = 1.6357
P/EG = 1.224
Revenue TTM = 3.33b USD
EBIT TTM = 310.8m USD
EBITDA TTM = 454.3m USD
Long Term Debt = 1.88b USD (from longTermDebt, last quarter)
Short Term Debt = 500k USD (from shortTermDebt, last quarter)
Debt = 1.95b USD (from shortLongTermDebtTotal, last quarter) + Leases 77.3m
Net Debt = 1.53b USD (calculated: Debt 1.95b - CCE 425.6m)
Enterprise Value = 5.59b USD (4.06b + Debt 1.95b - CCE 425.6m)
Interest Coverage Ratio = 3.10 (Ebit TTM 310.8m / Interest Expense TTM 100.3m)
EV/FCF = 102.5x (Enterprise Value 5.59b / FCF TTM 54.5m)
FCF Yield = 0.98% (FCF TTM 54.5m / Enterprise Value 5.59b)
FCF Margin = 1.64% (FCF TTM 54.5m / Revenue TTM 3.33b)
Net Margin = 5.16% (Net Income TTM 171.8m / Revenue TTM 3.33b)
Gross Margin = 32.15% ((Revenue TTM 3.33b - Cost of Revenue TTM 2.26b) / Revenue TTM)
Gross Margin QoQ = 33.54% (prev 32.17%)
Tobins Q-Ratio = 0.93 (Enterprise Value 5.59b / Total Assets 6.00b)
Interest Expense / Debt = 5.14% (Interest Expense 100.3m / Debt 1.95b)
Taxrate = 25.04% (57.3m / 228.8m)
NOPAT = 233.0m (EBIT 310.8m * (1 - 25.04%))
Current Ratio = 1.90 (Total Current Assets 1.53b / Total Current Liabilities 806.9m)
Debt / Equity = 0.80 (Debt 1.95b / totalStockholderEquity, last quarter 2.44b)
Debt / EBITDA = 3.36 (Net Debt 1.53b / EBITDA 454.3m)
Debt / FCF = 28.03 (Net Debt 1.53b / FCF TTM 54.5m)
Total Stockholder Equity = 2.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.83% (Net Income 171.8m / Total Assets 6.00b)
RoE = 7.17% (Net Income TTM 171.8m / Total Stockholder Equity 2.40b)
RoCE = 7.27% (EBIT 310.8m / Capital Employed (Equity 2.40b + L.T.Debt 1.88b))
RoIC = 4.63% (NOPAT 233.0m / Invested Capital 5.03b)
WACC = 8.13% (E(4.06b)/V(6.01b) * Re(10.19%) + D(1.95b)/V(6.01b) * Rd(5.14%) * (1-Tc(0.25)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.78 | Cagr: 0.10%
[DCF] Terminal Value 73.10% ; FCFF base≈92.6m ; Y1≈81.2m ; Y5≈65.6m
[DCF] Fair Price = N/A (negative equity: EV 1.05b - Net Debt 1.53b = -474.2m; debt exceeds intrinsic value)
EPS Correlation: 94.44 | EPS CAGR: 9.56% | SUE: 4.0 | # QB: 1
Revenue Correlation: 85.24 | Revenue CAGR: 1.78% | SUE: 1.75 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.80 | Chg30d=+8.30% | Revisions=+70% | Analysts=7
EPS current Year (2026-12-31): EPS=3.20 | Chg30d=+4.08% | Revisions=+70% | GrowthEPS=+13.5% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=3.50 | Chg30d=+3.32% | Revisions=+70% | GrowthEPS=+9.2% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: +88% (up=21, down=0)